Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma
Metrics: PDF 202 views | ?
1Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
2Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona, Catalonia, Spain
3Department of Radiology, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital, Girona, Spain
4ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain
5Girona Biomedical Research Institute (IDIBGi), Girona, Catalonia, Spain
6Department of Medical Sciences, Medical School, University of Girona, Girona, Spain
Published: July 01, 2023
Copyright: © 2023 Teixidor et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article has an addendum: Patient consent was required and obtained.
Original article: Oncotarget. 2018; 9:33043-33049. DOI: https://doi.org/10.18632/oncotarget.25984.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.